Enzo Biochem, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Segment reporting (Tables)

Segment reporting (Tables)

12 Months Ended

Jul. 31, 2014

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following financial information represents the operating results of the reportable segments of the Company:

Year ended July 31, 2014	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	58,689			—			—			—		$	58,689
Product revenues		—		$	32,850			—			—			32,850
Royalty and license fee income		—			4,408			—			—			4,408
Total revenues		58,689			37,258			—			—			95,947

Operating expenses:
Cost of clinical laboratory services		38,948			—			—			—			38,948
Cost of product revenues		—			15,320			—			—			15,320
Research and development		14			2,350		$	777			—			3,141
Selling, general and administrative		20,460			13,374			—		$	7,967			41,801
Provision for uncollectible accounts receivable		3,115			(52	)		—			—			3,063
Legal fee expense		736			940			—			5,278			6,954
Legal settlements, net		2,000			(5,100	)								(3,100	)
Total operating expenses		65,273			26,832			777			13,245			106,127

Operating (loss) income		(6,584	)		10,426			(777	)		(13,245	)		(10,180	)

Other income (expense)
Interest		(43	)		9			—			(174	)		(208	)
Other		56			95			—			43			194
Foreign exchange gain		—			289			—			—			289

(Loss) income before income taxes	$	(6,571	)	$	10,819		$	(777	)	$	(13,376	)	$	(9,905	)

Depreciation and amortization included above	$	1,415		$	2,455		$	7		$	94		$	3,971

Share-based compensation included in above:
Cost of clinical laboratory services	$	8		$	1			—			—		$	9
Research and development		—			1			—			—			1
Selling, general and administrative		36			6			—		$	542			584
Total	$	44		$	8			—		$	542		$	594

Capital expenditures	$	643		$	195			—			—		$	838

Year ended July 31, 2013	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	55,889			—			—			—		$	55,889
Product revenues		—		$	32,526			—			—			32,526
Royalty and license fee income		—			5,292			—			—			5,292
Total revenues		55,889			37,818			—			—			93,707

Operating expenses:
Cost of clinical laboratory services		38,251			—			—			—			38,251
Cost of product revenues		—			16,584			—			—			16,584
Research and development		294			2,356		$	1,239			—			3,889
Selling, general and administrative		19,942			15,511			—		$	8,201			43,654
Provision for uncollectible accounts receivable		4,232			264			—			—			4,496
Legal fee expense		316			57			—			5,440			5,813
Total operating expenses		63,035			34,772			1,239			13,641			112,687

Operating (loss) income		(7,146	)		3,046			(1,239	)		(13,641	)		(18,980	)

Other income (expense)
Interest		(46	)		13			—			(21	)		(54	)
Other		49			(71	)		—			27			5
Foreign exchange gain		—			80			—			—			80

(Loss) income before income taxes	$	(7,143	)	$	3,066		$	(1,239	)	$	(13,635	)	$	(18,949	)

Depreciation and amortization included above	$	1,377		$	3,102		$	22		$	104		$	4,605

Share-based compensation included in above:
Cost of clinical laboratory services	$	9			1			—			—		$	10
Research and development		—		$	2			—			—			2
Selling, general and administrative		36			10			—		$	487			533
Total	$	45		$	13			—		$	487		$	545

Capital expenditures	$	757		$	231			—			—		$	988

Year ended July 31, 2012	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	59,403			—			—			—		$	59,403
Product revenues		—		$	37,722			—			—			37,722
Royalty and license fee income		—			5,958			—			—			5,958
Total revenues		59,403			43,680			—			—			103,083

Operating expenses:
Cost of clinical laboratory services		36,305			—			—			—			36,305
Cost of product revenues		—			19,668			—			—			19,668
Research and development		299			4,308		$	1,686			—			6,293
Selling, general and administrative		20,856			18,305			—		$	8,767			47,928
Provision for uncollectible accounts receivable		4,987			117			—			—			5,104
Legal fee expense		262			536			—			2,926			3,724
Impairment charges		—			24,540			—			—			24,540
Total operating expenses		62,709			67,474			1,686			11,693			143,562


Operating loss		(3,306	)		(23,794	)		(1,686	)		(11,693	)		(40,479	)

Other income (expense)
Interest		(5	)		23			—			3			21
Other		28			27			—			22			77
Foreign exchange loss		—			(540	)		—			—			(540	)

Loss before income taxes	$	(3,283	)	$	(24,284	)	$	(1,686	)	$	(11,668	)	$	(40,921	)

Depreciation and amortization included above	$	1,092		$	3,217		$	43		$	125		$	4,477

Share-based compensation included in above:
Cost of clinical laboratory services	$	10						—			—		$	10
Research and development		—		$	4			—			—			4
Selling, general and administrative		49			59			—		$	597			705
Total	$	59		$	63			—		$	597		$	719

Capital expenditures	$	921		$	443			—			—		$	1,364

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]

Geographic financial information is as follows:

Net sales to unaffiliated customers:	2014		2013		2012
United States	$	84,389	$	80,559	$	87,776
Switzerland		4,130		5,499		6,802
United Kingdom		2,023		2,324		2,728
Other international countries		5,405		5,325		5,777
Total	$	95,947	$	93,707	$	103,083

Long-lived assets at July 31,
United States	$	20,854	$	23,136	$	25,081
Switzerland		1,629		1,984		2,223
United Kingdom		462		491		618
Other international countries		345		401		426
Total	$	23,290	$	26,012	$	28,348

Schedule of Segment Revenue By Geographical [Table Text Block]

The following is a summary of the Life Sciences segment revenues attributable to customers located in the United States and foreign countries:

	2014		2013		2012
United States	$	25,700	$	24,669	$	28,372
Foreign countries		11,558		13,149		15,308
	$	37,258	$	37,818	$	43,680

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details